


Amendments to the Specification

Please replace the paragraph at page 5, lines 10 through 14 with the following amended paragraph:

BRIEF DESCRIPTION OF THE FIGURES

The Figure represents the catalytic iron content (nmol/mg urinary creatinine) in urine obtained from humans with no kidney disease (control), with diabetic microalbuminuria (DM Micro), diabetic (DM) proteinuria, glomerulonephritis (~~GM~~) (GN) and ischemic nephropathy.

Please replace the paragraph at page 8, lines 13 through 15 with the following amended paragraph:



Please replace the paragraph at page 17, line 22 through page 18, line 3 with the following amended paragraph:

The phrase “reducing the severity” (also referred to herein as a reduction in the severity) when referring to a progressive kidney disease means any diminution, amelioration or decrease in progressive damage to the kidney that compromises the function of the kidney. Well- recognized indices to assess function of the kidney can be employed to determine a reduction in the severity of the kidney disease. These indices can include, for example, a reduction in protein content in urine, a reduction in blood urea nitrogen, a reduction in serum or plasma creatinine, ~~a decline~~ an increase in glomerular filtration rate, a delay in the onset of end-stage renal disease, or any combination thereof, compared to a sample obtained from the human prior to administering the iron chelator, or a control sample.

Please replace the Table 1 at page 37, line 1 through line 46 with the following amended

Table 1:

Table 1: Urinary Catalytic Iron In Patients with Progressive Kidney Disease

Age/Sex/Race	Diagnosis	24 hr prot (mg/24 hrs)	Serum Cr (mg/dl)	CrCl (ml/min)	Catalytic Iron (Nmole/mg creatinine)
20 F W	Membranous	8900	1.1	120.0	33.4
23 M W	Membranous	4200	2.3		22.3
50 F B	SLE	5000	1.9	57.0	90.7
51 F B	SLE	5000	1.4		9.1
64 M W	SLE	3700	0.9		11.0
45 F W	SLE	3700	0.6		69.0
38 F B	SLE	6843	4.4		70.0
38 F B	FSGS	5000	2.6		52.7
7 M W	FSGS	20790	2.1	30.6	48.6
15 F B	FSGS	2360	0.8	110.2	43.7
14 F B	FSGS	16350	2.3	38.6	17.3
32 M B	FSGS	300	2.2		20.1
40 F B	FSGS	5200	1.7		61.6
40 M W	FSGS		2.1		28.0
40 M B	FSGS	15730	3.3	20.0	118.0
11 F W	HSP	11120	0.6	139.3	26.1
<1 M W	HUS		0.7		84.2
16 M B	IgA	830	1.6	58.4	19.1
<1 M B	MPGN	2104	0.5	75.0	66.8
54 M	MPGN		3.8		43.0
40 M W	MPGN	16260			106.0
65 F W	Crecentic		5.9		5.4
Mean					48
SEM					7
Number					22
P					<0.0001

Ischemic Nephropathy					
45 F W	Isch Neph		1.8		92.0
80 F W	Isch Neph		2.0		96.0
Mean					94.0
SEM					2.0
Number					2
P					<0.01

SLE: Systemic Lupus Erythematosus; FSGS=Focal Segmental Glomerulosclerosis;
HSP=Henoch-Schonlein Purpura; HUS=Hemolytic Uremic Syndrome;
MPGN=Membranoproliferative Glomerulonephritis; Isch Neph=Ischemic Nephropathy
SLE, HSP, HUS and Ischemic Nephropathy are secondary causes of renal disease.
P compared to control value of 8.1 ± 1.4 , n=23, using unpaired t test

Isch Neph=Ischemic Nephropathy

prot=protein

Cr=creatinine

CrCl=creatinine Clearance